---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-209874"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T15:35:57.042091+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IO Biotech Q2 net loss $21.2M; Phase 3 melanoma trial reaches 225-patient milestone; $75M private placement closed

## Summary
- Net loss of $21.2M (vs $18.5M Q2 2022); R&D spend $16.5M on Phase 3 trial execution.
- Cash and equivalents $110.1M; expected to fund operations into Q4 2025.
- Phase 3 IOB-013/KN-D18 enrolled 225 patients; target raised to 380, full enrollment by end 2023.
- Interim ORR analysis one year post 225 randomized may support US accelerated BLA submission.
- Appointed Heidi Hunter to Board; Priyanka Belawat resigned; closed $75M private placement (37M shares+warrants).

## SEC filing metadata
- accession: 0001193125-23-209874
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312523209874/0001193125-23-209874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312523209874/d524431d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-209874
- JSON: https://secwatch.observer/filing/0001193125-23-209874.json
- Plain text: https://secwatch.observer/filing/0001193125-23-209874.txt

## Key facts
- Earnings Releases
  IO Biotech, Inc. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was $21.2 million.
  - Period: second quarter ended June 30, 2023
  - Net income: Net loss for the three months ended June 30, 2023 was $21.2 million
  - Result: reported results
  source text: Net loss for the three months ended June 30, 2023 was $21.2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312523209874/0001193125-23-209874-index.htm
- Executive change
  Priyanka Belawat resigned as Director at IO Biotech, Inc..
  - Action: resigned
  - Role: Director
  source text: On August 7, 2023, Priyanka Belawat, a member of the Board of Directors of the Company, notified the Company of her resignation from the Board, effective that same date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312523209874/0001193125-23-209874-index.htm
- Executive change
  Heidi Hunter was appointed as Class II director at IO Biotech, Inc..
  - Action: appointed
  - Role: Class II director
  source text: On August 8, 2023, the Company appointed Heidi Hunter as a Class II director of the Company, effective as of August 11, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312523209874/0001193125-23-209874-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.